Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT.
Arnon NaglerJacques-Emmanuel GalimardMyriam LabopinDidier BlaiseWilliam ArceseSilvia Maria TrisoliniDepei WuArnaud PigneuxGwendolyn Van GorkomMarie-Thérèse RubioTobias Gedde-DahlAnne HuynhFrancesco LanzaNorbert-Claude GorinMohamad MohtyPublished in: Cancer medicine (2022)
LFS and OS were inferior and relapse rate was higher in AML patients who received two inductions chemotherapy courses to reach CR1 before being autografted. AML patients who required 2 induction courses to achieve remission, may be offered allogeneic transplantation rather than an autologous one in an attempt to reduce their high RI and improve outcomes.
Keyphrases
- stem cell transplantation
- acute myeloid leukemia
- high dose
- bone marrow
- end stage renal disease
- cell therapy
- allogeneic hematopoietic stem cell transplantation
- ejection fraction
- newly diagnosed
- chronic kidney disease
- disease activity
- peritoneal dialysis
- type diabetes
- prognostic factors
- stem cells
- systemic lupus erythematosus
- radiation therapy
- squamous cell carcinoma
- locally advanced
- adipose tissue
- mesenchymal stem cells
- patient reported outcomes
- insulin resistance
- glycemic control